INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. This is an ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...
Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...
Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...
Recently, a research team led by Professors Dahong Zhang and Qi Zhang from the Urology Department and the Institute of Urology at Zhejiang Provincial People's Hospital and the Translational Medicine ...
The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva (nogapendekin alfa inbakicept) in ...
Bladder cancer is the 4th most prevalent cancer in men, 11th in women and presents one of the highest rates of post-treatment recurrence (70%) among malignancies. Despite its impact on human health, ...
LAS VEGAS -- Overactive bladder (OAB) symptoms in women improved rapidly and significantly following a single treatment with transvaginal radiofrequency (RF) nerve ablation, a small prospective study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results